

NEONATAL Medication Monograph

ADENOSINE

This document should be read in conjunction with this **DISCLAIMER**

Restricted: Requires Cardiologist review within 24 hours of initiation

Presentation	Vial: 6 mg/2 mL = 3000microg/mL		
Classification	Antiarrhythmic - rapid onset anti-arrhythmic action resulting in transient AV node block.		
Indication	Supraventricular tachycardia		
Dose	IV: Initial dose: 100 microgram/kg/dose Subsequent doses: Increase initial dose by 100 microgram/kg/dose increments every 2 minutes until return of sinus rhythm. Maximum dose: 300 microgram/kg/dose		
Monitoring	Continuous ECG monitoring, blood pressure and respiration monitoring.		
Dose Adjustment	Dose according to response The first dose should not exceed 6mg and the second dose should not exceed12mg. If multiple doses are required within 24hours; consult cardiologist.		
Guidelines & Resources	Arrhythmias Arrhythmias and Cardiac Arrest on NICU: Treatment Algorithms		
Compatible Fluids	Sodium Chloride 0.9%, Glucose 5%.		
Administration	Refer to next Page		

Administration	I <u>IV:</u>			
	Rapid IV bolus over 1 to 2 seconds preferably into a central line (UVC or short jugular/ femoral CVC, <u>not</u> PICC)			
	or a peripheral line into large proximal vein (antecubital fossa ideal)			
	or intraosseous if difficult access.			
	Follow with rapid 10mL sodium chloride 0.9% flush.			
	Note: IV administration into lower extremities or into smaller veins may result in therapeutic failure, however, if this is only access available then attempt this route).			
	**Administer by ONE person using 2 syringes (one with adenosine dose and the other with 10mL sodium chloride 0.9% flush) connected via a 3- way tap. The drug administrator may instruct a second person to turn the 3-way tap.			
Preparation	<u>IV:</u>			
	Doses greater than 600 micrograms			
	600microg = 0.2mL			
	No dilution required.			
	Doses less than 600 micrograms			
	Dose may be diluted as described below.			
	Compatible Fluid: Sodium Chloride 0.9%, Glucose 5%			
	Dilution			
	Dilute 1ml (3000 microg) of adenosine with 9 ml of compatible fluid.			
	Total volume is $10mL = 3000microg/10mL$			
	Final Concentration = 300 microg/mL			
	Discard diluted solution immediately after use.			
Adverse	Flushing, irritability, transient arrhythmias, hypotension			
Reactions	Dyspnoea, bradycardia, bronchial constriction			
Storage	Store below 25°C			
0	Do NOT refrigerate; crystallisation will occur.			
Interactions	The levels/effects of adenosine may be decreased by caffeine or caffeine containing products.			
Notes	Adenosine has a very short duration of effect (half-life 1-10 seconds)			

Advanced Paediatric Life Support. Supraventricular Tachycardia (SVT) management. In: APLS [Internet]. Melbourne (Victoria); 2017 [cited 2019 Apr 2]. Available from: <u>https://www.apls.org.au/page/algorithms</u>
Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 23rd ed. Hudson (Ohio): Lexicomp; 2017. 2,401 p68.
Truven Health Analytics. Adenosine. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Mar 15]. Available from: https://neofax.micromedexsolutions.com/
Australian Medicines Handbook. Adenosine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2019 Mar 15]. Available from: https://amhonline.amh.net.au/
Society of Hospital Pharmacists of Australia. Adenosine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Mar 15]. Available from: <u>http://aidh.hcn.com.au</u>

Keywords:	Adenosine, supraventricular tachycardia, SVT				
Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	May 2008	Version:	3.3		
Last reviewed:	April 2019, amended February 2020	Next review date:	February 2023		
Endorsed by:	Neonatal Directorate Management Group	Date:	February 2020		
Standards Applicable:	NSQHS Standards: 1				
Printed or personally saved electronic copies of this document are considered uncontrolled.					
Access the current version from the WNHS website.					

© Department of Health Western Australia 2019